🔗 Share this article

Given that the United States undertakes sweeping adjustments to its immunization schedules, one figure has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who first made her name by expressing skepticism about COVID-19 vaccinations in the global health crisis and has focused upon potential fatalities after COVID-19 vaccination in her brief time at the Food and Drug Administration.

Scheduled Changes to Childhood Immunization Schedule

Agency leaders had intended to unveil major changes to the pediatric vaccine schedule earlier this month, bringing the US with Denmark’s vaccine program, it is understood – a substantial departure that would place the US out of step with many the world with no evidence for improved outcomes. The announcement has been delayed until the new year.

Rather than the director of the vaccine center, Dr. Høeg is listed to address the audience at the gathering. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth person to head the division this year.

A Shift at the FDA

This interim role might represent a closer partnership between the pharmaceutical and biologics branches as Høeg and Dr. Prasad strengthen their influence at the FDA – and it suggests a greater focus upon dismantling long-standing vaccines at the FDA.

The new acting director has repeatedly called for discontinuing specific pediatric vaccine recommendations in the US so as to align more in line with Denmark's approach, a nation with nationalized medicine and a population approximately the population of Wisconsin’s.

So far public appearances, she has continued to focus on immunizations – typically the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Concerns Over Expertise

The appointee has little discernible track record in pharmaceutical research, regulation or administrative roles, which has been standard for previous leaders of the CBER. She has been employed at the FDA as a senior adviser to the agency head and CBER since earlier this year.

“She appears not to have the requisite experience” for running the drug-regulation department, remarked Dr. Jonathan Howard. “She’s never run a clinical trial. She is not versed in leading a major agency. She has no expertise in industry regulation.”

Former directors of CBER would “grasp regulatory frameworks and the underlying principles of pharmaceutical innovation”, said a former acting FDA commissioner. “Objectively, she doesn’t have the type of experience that previous people who ran the center have had.”

CDER has an immense portfolio at the agency, the former commissioner stated.

“Many people just focuses on the innovative therapies, but the generic program clears thousands of generic medications. There’s a biosimilars program, OTC medication office and more, and each of these must be supervised,” Woodcock explained. “The area you neglect, that’s the thing that I always told people is going to cause problems.”

There is also, a major management element to the position, which manages more than 5,000 staff members. “It is a massive management job, if you perform it correctly,” she concluded.

Agency Reaction and Disputed Policies

Regarding questions about Dr. Høeg's qualifications and whether this selection signifies increased cooperation among agency officials on immunizations, a representative stated that the “questions stem from incorrect premises”.

“Her experience matches the duties of her position,” the representative said, citing the time Høeg spent advising the agency head on “drug safety and oversight research, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg takes over the agency head's controversial priority voucher program, a controversial one-day drug-approval program that apparently troubled her preceding directors. “How are these drugs being picked for this fast-track system? Who is making the choices?” Dr. Howard questioned. “There is a lot of secrecy occurring at the agency right now.”

In general, he remarked, “the agency seems to be moving towards more relaxed oversight of most medications, except for vaccines.”

Documented Track Record on Vaccines

Regarding immunizations, Høeg has a more established, if concerning, past, Howard observe. She released a study using unconfirmed crowd-sourced reports to estimate the incidence of myocarditis following Covid immunization. She counseled the Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccinations are pose a greater threat than they are.

Part of her “wish list” for the current federal leadership encompassed revising guidelines for new vaccines and discontinuing “optional” vaccines, she remarked post-election on a podcast. At the agency, Dr. Høeg has reportedly proposed excluding young men from obtaining Covid vaccines.

“She is an thorough ideologue who begins with her conclusions and works backwards to fit the data in a very disingenuous, fraudulent manner,” Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg aligned with fellow skeptics, {like|